Table 1.

Univariate analysis of factors associated with ACEI/ARB usea

VariablePatients not Using ACEI/ARBPatients Using ACEI/ARBP
Age (yr)65.9 (12.1)65.9 (10.7)0.9000
Female gender133 (20.40%)150 (21.22%)0.7107
BMI28.829.90.0006
White race563 (86.35%)613 (90.10%)0.8482
Elective/urgent surgery600 (92.02%)637 (90.24%)0.2486
Risk category (ASA 4/5)179 (27.45%)244 (34.51%)0.0050
Diabetes147 (22.55%)311 (43.99%)<0.0001
Surgery type (CABG)564 (86.50%)619 (87.55%)0.5647
Hypertension454 (69.63%)638 (90.24%)<0.0001
CHF83 (12.73%)185 (26.17%)<0.0001
COPD107 (16.41%)136 (19.24%)0.1745
Liver disease30 (4.60%)22 (3.11%)0.1527
GI comorbidity115 (17.64%)126 (17.82%)0.9294
Neurologic disease112 (17.18%)154 (21.78%)0.0326
Arthritis165 (25.35%)198 (28.01%)0.2685
Use of NSAID69 (10.58%)75 (10.61%)0.9879
On pump457 (70.20%)481 (68.30%)0.4500
Intraoperative hypotension270 (41.41%)337 (47.67%)0.0205
Postoperative hypotension86 (13.19%)92 (13.01%)0.9228
AKI (present)179 (36.70%)212 (43.40%)0.0006
  • a ASA, American Society of Anesthesiologists Risk Score; ACEI, angiotensin-converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; NSAID, nonsteroidal anti-inflammatory drugs.